The soaring costs of prescription drugs in the United States have become a major concern for millions of Americans. The debate over pharmaceutical pricing has intensified as healthcare expenses continue to rise. One of the key players in this debate is the pharmaceutical industry, often called “Big Pharma.” Big Pharma has consistently argued against price negotiations, claiming it would stifle innovation and limit patient access to cutting-edge treatments. However, there is a growing skepticism among the public and policymakers about the credibility of these arguments.
BIO and the Pharmaceutical Research and Manufacturers of America continue to push their big lie that having the government negotiate prices for medicare will continue to hurt investment even though 83% of the public say they favor allowing the federal government to negotiate with drug companies to lower drug prices on behalf of people enrolled in Medicare. It’s part of PhRMA’s big lie used to buy politicians.